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The emergence of antimicrobial-resistant bacteria is an increasingly serious threat to global
health, necessitating the development of innovative antimicrobials. Here we report the
development of a series of CRISPR-Cas13a-based antibacterial nucleocapsids, termed Cap-
sidCas13a(s), capable of sequence-specific killing of carbapenem-resistant Escherichia coli and
methicillin-resistant Staphylococcus aureus by recognizing corresponding antimicrobial resis-
tance genes. CapsidCas13a constructs are generated by packaging programmed CRISPR-
Cas13a into a bacteriophage capsid to target antimicrobial resistance genes. Contrary to
Cas9-based antimicrobials that lack bacterial killing capacity when the target genes are
located on a plasmid, the CapsidCas13a(s) exhibit strong bacterial killing activities upon
recognizing target genes regardless of their location. Moreover, we also demonstrate that the
CapsidCas13a(s) can be applied to detect bacterial genes through gene-specific depletion of
bacteria without employing nucleic acid manipulation and optical visualization devices. Our
data underscore the potential of CapsidCas13a(s) as both therapeutic agents against
antimicrobial-resistant bacteria and nonchemical agents for detection of bacterial genes.
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The emergence and spread of antimicrobial resistanceamong pathogenic bacteria has been a growing globalpublic health concern for several decades1. According to
the recent CDC’s report on antimicrobial resistance, >2.8 million
antimicrobial-resistant infections occur in the U.S. each year, and
>35,000 people die as a result2. It is also predicted that
antimicrobial-resistant (AMR) pathogens will cause 10 million
fatalities per year by 2050 if new antimicrobial strategies are not
developed3. In fact, the emergence of AMR bacteria has led to the
post-antibiotic era, in which many currently available anti-
microbials are no longer effective. This is due in part to the
decline in antibiotic innovation, as no new class of antibiotics has
been developed against Gram-negative bacteria in >45 years, and
only a limited number of antibiotics were in either phase II or III
clinical trials4. Therefore, there is an urgent need for new stra-
tegies to develop alternative therapeutic approaches to prevent
infections of AMR bacteria.
To this end, various nucleic acid-based antibacterials, peptides,
bacteriophage therapies, antibodies, bacteriocins, and anti-virulence
compounds have been recently developed5. Among these, CRISPR
(clustered regularly interspaced short palindromic repeats)-Cas3-
and Cas9-encoding phages provide a means to combat such threats
by selectively killing AMR bacteria6. The CRISPR-Cas3 and
CRISPR-Cas9 genome-editing constructs, which were designed to
target AMR genes, were delivered into bacteria by packaging them
into phages7–11 to achieve AMR gene-specific bacterial killing7–12
and prevent the spread of AMR genes7. However, because DNA
cleavage of plasmid DNA does not result in bacterial death, at least
not in the absence of other confounding variables, such as a
toxin–antitoxin system, this strategy is ineffective in targeting bac-
teria with plasmid-borne AMR genes9.
CRISPR-Cas13a is a CRISPR-Cas type VI class 2 system and is
characterized by RNA-guided single-stranded RNA (ssRNA)
cleavage activity13,14. A 2016 study by Abudayyeh et al. demon-
strated that CRISPR-Cas13a has promiscuous ssRNA cleavage
activities and restricts host bacteria growth due to the degradation
of the bacterial RNAs (ref. 14). This has turned out to be a defense
system against phages15. When phages infect bacteria, CRISPR-
Cas13a recognizes transcript of phage genome, which leads to
nonspecific degradation of bacterial transcripts and arrests bac-
terial cell growth to prevent the spread of infection. Recently, we
identified four different subtypes of CRISPR-Cas13a systems
from 11 strains of six Leptotrichia species16. Among them
CRISPR-Cas13a form Leptotrichia shahii (LshCas13a) had a
significant inhibition effect on bacterial growth, consistent with
the observation by Abudayyeh et al.14. We here report success in
developing sequence-specific antimicrobials by packaging the
LshCas13a into bacteriophage capsids, which can be used as both
therapeutic agents against AMR bacterial infections and non-
chemical agents to detect bacterial genes for diagnosis.
Results
Bactericidal activity of Cas13a. First, we verified the growth
inhibition ability of CRISPR-Cas13a (LshCas13a) in comparison
with CRISPR-Cas9 by using Escherichia coli carrying the carbape-
nem resistance gene blaIMP-1 on a chromosome or plasmid. To this
end, we constructed two plasmids (pKLC21 and pKLC54) harboring
CRISPR-Cas13a or CRISPR-Cas9 with spacers targeting blaIMP-1
(spacer sequence was optimized, see later), and introduced them
into the E. coli, respectively, to test their growth inhibition effect
against the host cells carrying blaIMP-1 (Fig. 1a). As expected, the
LshCas13a with targeting blaIMP-1 decreased the number of bacteria
by two to three orders of magnitude against the bacteria carrying
blaIMP-1 both on chromosome (from 2.6 × 1010 to 2.0 × 108 CFU/
ml) and plasmid (from 2.3 × 1010 to 8.7 × 106 CFU/ml). However
the CRISPR-Cas9 decreased the number of bacteria by three orders
of magnitude against the bacteria carrying the blaIMP-1 only on the
chromosome (from 6.3 × 1010 to 3.6 × 107 CFU/ml), but not on the
plasmid (from 2.8 × 1010 to 2.2 × 1010 CFU/ml), when compared
with their respective nontargeting controls (Fig. 1b, c). These results
agreed with the fact that while CRISPR-Cas9 caused cell death by
double-strand DNA breaks, CRISPR-Cas13a induced cell dormancy
by collateral nonspecific cleavage of RNA (ref. 14). However, it is not
clear whether the above decrements in cell number by Cas13a is due
to cell death.
In order to determine whether Cas13a causes cell death or not,
we have constructed a system in which CRISPR-Cas13a targeting
mRNA of red fluorescent protein (RFP) transcribed from plasmid
inhibits the growth of bacteria harboring RFP, following the
method by Abudayyeh et al.14. We carried out the experiment in
broth culture medium using LshCas13a by introducing an
anhydrotetracycline (aTc)-inducible RFP plasmid (pKLC56-rfp),
as well as an RFP-targeting LshCas13a (Cas13a_rfp) into E. coli
(Fig. 1d), where the same spacer sequence used by Abudayyeh
et al. was used to target rfp (ref. 14). We observed the similar cell
growth restriction by LshCas13a upon induction of the target rfp
transcription compared to nontarget control and non-induction
control (Fig. 1e, left and middle panels). Interestingly, when the
same experiment was carried out using blaIMP-1 as target gene, the
bacteria growth curve stopped rising upon induction of blaIMP-1
transcription (Fig. 1e, right panel), indicating cell growth might
be completely stopped due to the cell death or dormancy. To
make this point clear, viable cells carrying blaIMP-1-targeting
spacer were counted during the culture with and without aTc
induction of blaIMP-1 transcription. As seen in Fig. 1f, the number
of viable cells were decreased by about three orders of magnitude
from 5.5 × 106 to 8.8 × 103 during the 8 h upon induction of
blaIMP-1 transcription. We interpreted these results as demonstra-
tion of CRISPR-Cas13a-mediated sequence-specific killing of host
cells. However, reasons of the viable cells that are in dormancy15
or resistant to CRISPR-Cas13a are not clear at the moment, but
we did not find any mutation in target sequence after sequencing
32 randomly selected colonies from the above two experiments
(Fig. 1b). We also observed that the induction of blaIMP-1
transcription inhibited the host cell growth (Fig. 1e, right panel),
which could be attributed to fitness cost of blaIMP-1 over-
expression. It is well known that the accumulation of carbape-
nemase compromises the bacterial growth17,18.
Packaging of CRISPR-Cas13a into bacteriophage capsid.
Having verified the bactericidal activity of the CRISPR-
Cas13a_blaIMP-1 construct against blaIMP-1-positive bacteria, we
came up with the idea that AMR bacteria-specific CapsidCas13a
constructs could be synthesized by loading the CRISPR-Cas13a
system into a phage capsid. The CRISPR-Cas13a_blaIMP-1 was
loaded into E. coli phage M13 capsid, to generate EC-
CapsidCas13a_blaIMP-1 (Fig. 2a), which demonstrated sequence-
specific killing activity against bacteria carrying the blaIMP-1 gene
in an EC-CapsidCas13a_blaIMP-1 concentration-dependent man-
ner (Fig. 2b). Subsequently, we confirmed the same sequence-
specific killing activities with a series of CapsidCas13a constructs
programmed to target different genotypes of carbapenem-
resistant genes (blaIMP-1, blaOXA-48, blaVIM-2, blaNDM-1, and
blaKPC-2) and colistin-resistant genes (mcr-1 and mcr-2), all of
which are currently a problem in the clinical setting (Fig. 2c,
Supplementary Fig. 1). Conversely, nontargeting CapsidCas13a
(with nontargeting spacer) killed no bacteria under any circum-
stance, indicating that this construct has robust specificity for
gene-directed antimicrobial therapy against AMR bacterial
infections.
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Fig. 1 Sequence-specific bactericidal activity of CRISPR-Cas13a. a A schematic diagram of transformation of CRISPR-Cas13a and CRISPR-Cas9 with
targeting blaIMP-1 into blaIMP-1-expressing E. coli STBL3. b E. coli STBL3 expressing blaIMP-1 from a plasmid (plasmid-borne blaIMP-1) and chromosome
(chromosome-borne blaIMP-1) were prepared, and transformed with CRISPR-Cas13a or CRISPR-Cas9, both with spacer targeting blaIMP-1 or no spacer
(nontargeting). The resulting transformants were plated on an LB plate containing kanamycin (Km) to test sequence-specific bacterial killing by CRISPR-
Cas13a and CRISPR-Cas9. Km was used to maintain the plasmids. c The number of bacteria on the plate obtained in the experiment of b was counted. The
statistical significance was determined by two-sided Student’s t-test. Each bar represents the mean with standard deviation (n= 3). d A schematic diagram
of the experiment to test CRISPR-Cas13a-dependent cell growth inhibition. Anhydrotetracycline (aTc)-inducible blaIMP-1- or rfp-expression plasmid
(pKLC56) was co-transformed with pKLC21 plasmid expressing CRISPR-Cas13a with spacer targeting blaIMP-1 or rfp into E. coli STBL3. The resulting
transformants were then cultured and the aTc induction in the presence of the antibiotics Km and Cm (Km and Cm for maintaining plasmids) was carried
out at the indicated time points. Thereafter, the OD values were measured every hour. e Growth curves were plotted. Each line of the growth curves
represents the mean with standard deviation. f The number of viable cells was counted to calculate the ratio of cell death caused by blaIMP-1-targeting
CRISPR-Cas13a. The bacterial culture prepared in d was diluted to 1/100, then aTc was added to induce blaIMP-1. Km and Cm were also added to maintain
the CRISPR-Cas13a and the aTc-inducible blaIMP-1 plasmids. Thereafter, the bacterial cultures were sampled at the indicated time points, and the number of
surviving bacteria was counted on fresh LB plates. Each bar represents the mean with standard deviation of four biological replicates. p-values were
determined by two-sided Student’s t-test. Source data are available in the Source Data file.
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In order to compare the characteristics of CapsidCas13a with
previously reported Cas9-based antimicrobial agents, we generated
a Cas9-based EC-CapsidCas9_blaNDM-1 construct with the same
protocol, but in this instance CRISPR-Cas13a_blaNDM-1 was
replaced with CRISPR-Cas9_blaNDM-1 and its bactericidal manner
was compared with that of EC-CapsidCas13a_blaNDM-1. As
expected, EC-CapsidCas9_blaNDM-1 killed only the bacteria with
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Fig. 2 In vivo sequence-specific bactericidal activity of CapsidCas13a. a Graphical concept model depicting the mode of action of CapsidCas13a, with
blaIMP-1-targeting CRISPR-Cas13a packaged into E. coli M13 phage capsid (EC-CapsidCas13a-blaIMP-1) for delivery into host bacterial cells during the normal
course of viral infection. In the presence of the target gene (E. coli carrying blaIMP-1), CRISPR-Cas13a will be activated and the subsequent non-sequence-
specific RNase activity will result in host cell death. In the absence of the target gene (E. coli without blaIMP-1), CRISPR-Cas13a will not be activated and
there will be no subsequent cell death. b–d Spot assay with generated CapsidCas13a(s) on bacterial lawn of E. coli NEB5α F′Iq to test bactericidal activity. A
clear lysis zone of the spotted area represents bacterial killing. NEB5α F′Iq carrying blaIMP-1 expression vector and empty vector (control) were infected with
tenfold serial dilutions of EC-CapsidCas13a-blaIMP-1 in the presence or absence of L-arabinose for inducing blaIMP-1 expression (b); CapsidCas13a(s)
programmed to target different carbapenem resistance genes (blaIMP-1, blaOXA-48, blaVIM-2, blaNDM-1, and blaKPC-2) and colistin resistance genes (mcr-1 and
mcr-2) were spotted on a series of NEB5α F′Iq strains expressing each of the resistance genes (c); comparison of bactericidal activity between CRISPR-Cas9
and CRISPR-Cas13a. Nontargeting and blaNDM-1-targeting CapsidCas13a and CapsidCas9, in tenfold serial dilutions, were spotted on lawn of NEB5α F′Iq
with or without expression of blaNDM-1 on plasmid or chromosome (d). All assays were replicated three times.
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killed the bacteria that carried the target gene on either the
chromosome or plasmid (Fig. 2d). Since many clinically important
AMR genes, including carbapenem-resistant genes found in
Enterobacteriaceae are encoded on plasmids19,20, CapsidCas13a
was expected to be superior to CapsidCas9 in light of the
killing efficiency. Besides, previous studies have suggested that
CRISPR-Cas9 is prone to unexpected genetic mutations due to
its DNA cleavage activity21–23. On the contrary, instead of the
direct cleavage of DNA, CapsidCas13a targets bacterial
mRNA. Therefore, unexpected genetic mutations of the bacteria
are less likely to occur due to the action of Cas13a. Although
an intensive study is needed, at least, as mentioned above we
did not find any mutation in target genes by sequencing
32 Cas13a-resistant colonies. These characteristics showed a
different potential of Cas13a as an antimicrobial agent compared
with Cas9.
In order to determine whether the CapsidCas13a(s) can
selectively kill target bacteria among a mixed population of
AMR bacteria, an artificial mixture of E. coli NEB5α F′Iq
expressing the plasmid-borne carbapenem resistance gene
blaIMP-1, the colistin resistance gene mcr-2, or with no resistance
gene as a control, was treated with single-dose of each gene-
specific EC-CapsidCas13a construct (i.e., EC-CapsidCas13a_
blaIMP-1 for targeting blaIMP-1, and EC-CapsidCas13a_mcr-2 for
targeting mcr-2). Subsequently, the abundance of each bacterial
strain was determined. As shown in Fig. 3, the percentage of cell
numbers of NEB5α F′Iq (blaIMP-1) and NEB5α F′Iq (mcr-2)
decreased significantly from 30.5% and 35.0% to 3.5% and 1.9%,
respectively when the cell mixtures were treated with EC-
CapsidCas13a_blaIMP-1 and EC-CapsidCas13a_mcr-2, respec-
tively. Meanwhile there was no change in the abundance of cell
populations after being treated by EC-CapsidCas13a with
nontargeting spacer control. These sequence-specific killing
activities of CapsidCas13a(s) demonstrate their potential as
microbial control agents that can modify or manipulate the
bacterial flora without affecting undesired bacterial populations
by killing those with specific genomic contents. Besides
demonstrating of the versatility of CapsidCas13a, we investigated
its in vivo therapeutic efficacy using a Galleria mellonella larvae
infection model. Administration of EC-CapsidCas13a_blaIMP-1 to
G. mellonella larvae infected with E. coli R10-61 expressing
blaIMP-1 showed significantly improved survival over no treat-
ment (p= 0.0016) or a CapsidCas13a carrying nontargeting
spacer, as a control (p= 0.044) (Fig. 4). This outcome further
strengthened the therapeutic prospects of the CapsidCas13a
constructs for treatment of infections with AMR bacteria.
Application to bacterial gene detection. Because the prevalence
of stealth bacteria (carrying AMR genes but not identifiable by
existing antibiotic susceptibility tests) has been increasing24, a
simple and easy-to-use detection method for such strains is
required in the clinical setting. To this end, the CapsidCas13a
constructs were modified for the detection of bacterial AMR
genes. First, the spacer sequence of EC-CapsidCas13a_blaIMP-1
targeting the blaIMP-1 gene was optimized in order to improve the
killing efficiency. The optimization started with the construction
of a CRISPR-Cas13a expression plasmid library, in which
121 spacer sequences targeting different positions throughout the
whole blaIMP-1 were inserted, each as one, into the CRISPR array.
Then, all plasmids were individually transformed into blaIMP-1-
expressing E. coli cells and the resulting transformants were
analyzed to identify the most effective spacer sequence (Supple-
mentary Fig. 2a). The calculation of the number of spacer reads
after deep sequencing of the total plasmid DNAs extracted from
the transformants found that all of the tested spacer sequences
mediated target-specific bacterial killing, at least to some extent,
when judged by the depletion rate of the plasmid DNAs (Sup-
plementary Fig. 2b). The depletion rate was calculated by nor-
malizing the number of reads from cells expressing blaIMP-1 with
that of non-blaIMP-1--expression. Among these, 13 spacer




























Fig. 3 Potential of CapsidCas13a as a tool for modifying bacterial flora.
Programmed CapsidCas13a altered the composition of bacterial population. A
mixed cell population was prepared by mixing E. coli NEB5α F′Iq (control) with
equal numbers of NEB5α F′Iq expressing blaIMP-1 and mcr-2, respectively. The
cell mixtures were then independently treated with blaIMP-1-targeting, mcr-2-
targeting, and nontargeting CapsidCas13a. Note that each AMR gene-
targeting CapsidCas13a reduced the corresponding target cell population. The
percentage represents the mean of three biological replicates. Source data are



























Fig. 4 Potential of CapsidCas13a as a therapeutic against AMR bacteria
infections. Examination of the therapeutic effect of EC-CapsidCas13a-
blaIMP-1 using a Galleria mellonella infection model. Administration of EC-
CapsidCas13a-blaIMP-1 (MOI 100) into G. mellonella larvae infected with
R10-61 (carbapenem-resistant clinical isolates of E. coli carrying blaIMP-1)
significantly improved host survival compared to controls, EC-
CapsidCas13a-nontargeting (p= 0.044), and phosphate-buffered saline
(PBS; p= 0.0016). The p-value between two groups infected with R10-61,
and treated with EC-CapsidCas13a-nontargeting and PBS was 0.30. The p-
values are calculated by log-rank test. The results are presented as the
aggregate values of three independent experiments performed using ten
larvae per group. Source data are available in the Source Data file.
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The blaIMP-1_563 spacer sequence GACTTTGGCCAAGCTTC
TATATTTGCGT, which had the highest depletion rate of 99.7,
was chosen as the best spacer sequence for use in subsequent
experiments (Supplementary Fig. 2c, Supplementary Table 4).
Then, the carrier M13 phage was replaced with the lysogenic
phage Φ80 for use with the phage-inducible chromosomal island
(PICI) packaging system (Supplementary Fig. 3)25,26, which is
more flexible in genome manipulation. Finally, the kanamycin
(Km) resistance gene (KanR) was inserted as a selection marker
to generate the constructs of PICI-based EC-CapsidCas13a::
KanR_blaIMP-1 and EC-CapsidCas13a::KanR_nontargeting as a
nontargeting spacer control (Fig. 5a).
Next, we tested the detection efficiency of the constructs for
blaIMP-1 by spotting 2 µL of tenfold serial dilutions of EC-
CapsidCas13a::KanR_blaIMP-1 and EC-CapsidCas13a::KanR_-
nontargeting onto fresh top agar lawns of the test strains in
Luria-Bertani (LB) agar with or without supplementation of Km
(Fig. 5b). To improve the efficiency, we opted to determine the
bacterial killing effect against Km-resistant cells on Km plates
(Fig. 5c), rather than assessing the bacterial killing effect against
original cells on Km-free plates (Fig. 5d). When the EC-
CapsidCas13a::KanR_blaIMP-1 carrying the Km resistance gene
was applied on the soft agar bacterial lawn grown on bottom agar
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LB Km plate EC-CapsidCas13a::
KanR_nontargeting





























Fig. 5 Potential use of CapsidCas13a for bacterial gene detection. a A schematic illustration of generation of PICI-based EC-CapsidCas13a targeting
blaIMP-1. Mitomycin C induction promotes the packaging of PICImid carrying a CRISPR-Cas13a system and kanamycin (Km) resistance gene into the capsid
of helper phage Φ80. b–d Bactericidal activity test of PICI-based EC-CapsidCas13a::KanR-blaIMP-1 (in tenfold serial dilutions) against E. coli MC1061 with or
without the expression of target gene was carried out on LB agar plates (b); and the test results were judged by observing bacterial growth on LB bottom
agar plates supplemented with Km (c), or observation of cell lysis on drug-free LB bottom agar plates (d); noting that the former assay had an enhanced
sensitivity by about three orders of magnitude against the bacteria carrying target gene. e–j The PICI-based EC-CapsidCas13a(s) were applicable to detect
various carbapenem resistance genes (blaIMP-1, blaOXA-48, and blaVIM-2) regardless of their location on either the plasmid or chromosome (e, f), whereas
EC-CapsidCas9 could detect genes located on the chromosome but not on the plasmid (g); and the PICI-based EC-CapsidCas13a(s) also effectively
detected toxin-encoded genes (h), differentiated different genes located on the same plasmid (i), and were also applicable to clinical isolates (j, left panel)
as being verified by PCR (j, right panel). k SA-CapsidCas13a::TetR-mecA generated by packaging mecA-targeting CRISPR-Cas13a into capsid of S. aureus
phage 80α exhibited mecA-specific bactericidal activity against MRSA, but not S. aureus strains deficient in mecA. All assays were replicated three times.
Uncropped images of the gels are available in the Supplementary Information.
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resistance and, hence, could grow in the presence of Km.
Nevertheless, with the bacterial cells carrying the target AMR
gene blaIMP-1, there was no observable growth due to the
bactericidal effect of the CRISPR-Cas13a construct (Fig. 5c). This
method was shown to be almost three orders of magnitude more
sensitive than direct observation of the bacterial growth inhibition
on Km-free plates (Fig. 5d). We further confirmed the efficiency
of this system, with the use of the M13 capsid-based EC-
CapsidM13Cas13a::KanR_blaIMP-1 construct (Supplementary
Fig. 4a–c). A subsequent experiment showed that the target
AMR genes of interest located on either the plasmid or
chromosome could be precisely detected (Fig. 5e, f, Supplemen-
tary Fig. 4d, e), as expected, whereas CRISPR-Cas9 construct
could detect only the genes located on a chromosome but not on
a plasmid (Fig. 5g). The detection ability was further confirmed
with the CapsidCas13a constructs targeting other AMR genes
blaOXA-48 and blaVIM-2 (Fig. 5e, f), toxin genes stx1 and stx2
(Fig. 5h), and two genes (blaIMP-1 and mcr-2) located on the same
plasmid (Fig. 5i), indicating that this method is applicable for the
detection of any bacterial genes regardless of their location on
bacterial chromosome or plasmid. Although the sensitivity was
slightly lower, it was even possible to detect target genes by
directly spotting the CapsidCas13a(s) onto the bacteria swabbed
on an agar plate instead of using the soft agar overlay method
(Supplementary Fig. 5).
We also tried to apply the CapsidCas13a constructs to detect
carbapenem-resistant clinical isolates of E. coli carrying blaIMP-1
or blaNDM-1. As these strains were not susceptible to Km, the
KanR of EC-CapsidCas13a::KanR was replaced with the hygro-
mycin (Hygro) resistance gene, HygroR, to generate the
constructs EC-CapsidCas13a::HygroR_blaIMP-1 and EC-Capsid-
Cas13a::HygroR_blaNDM-1. The test results with these two
CapsidCas13a(s) showed that the E. coli clinical isolates carrying
blaIMP-1 and blaNDM-1 were precisely detected, which was
consistent with the results of polymerase chain reaction (PCR)
analysis (Fig. 5j, Supplementary Fig. 5d), suggesting that the
CapsidCas13a(s) can be applied to detect bacterial genes. With
regard to the application potential of CRISPR-Cas13a, our data
demonstrated above has opened up a new field in which it can be
developed not only as an antibacterial therapeutic agent, but also
as a new bacterial identification system where no nucleic acid
manipulation is necessary once the CapsidCas13a(s) are estab-
lished. There was an elegant report on the CRISPR-Cas13-based
nucleic acid detection method, called as SHERLOCK system,
which was developed by combination of nucleic acid amplifica-
tion technique and CRISPR-Cas13. This method can detect DNA
or RNA in vitro with attomolar level sensitivity27. In contrast, the
proposed detection system using the CapsidCas13a constructs
can be performed without amplification of DNA or RNA,
electrophoresis equipment or optical devices, as only bacterial
culture plates are required. In addition, >1010 transducing
forming units (TFU) of CapsidCas13a constructs can be
harvested per liter of host bacterial culture, and only 2–3 µL of
105 constructs per mL of solution is required for a single spot test
to accurately determine the presence or absence of target genes.
Although these features highlight the elegant potential of
CapsidCas13a(s) for bacterial gene detection, there are still
limitations, at least: (1) it is necessary to construct corresponding
CapsidCas13a for each bacterial species and gene, (2) turnaround
time for test results can be long since interpretation of the results
is dependent on bacterial growth, (3) it cannot be used when the
bacteria cannot be cultured or the target gene is not transcribed.
Staphylococcus aureus CapsidCas13a. Lastly, in addition to
demonstrating the bactericidal activity of CRISPR-Cas13a against
Gram-negative bacteria, we also attempted to confirm the col-
lateral activity of CRISPR-Cas13a against Gram-positive bacteria
using Staphylococcus aureus. First, a set of E. coli–S. aureus shuttle
vectors, namely pKLC4(s), were generated carrying the CRISPR-
Cas13a construct with or without a spacer sequence targeting the
S. aureus rpsE genes. Transformation of the vector into S. aureus
strain RN4220 showed that the bactericidal activity of CRISPR-
Cas13a with an appropriate spacer sequence was similar to that in
E. coli (Supplementary Fig. 6a). Then, a SA-CapsidCas13a_mecA
construct was produced to target methicillin-resistant gene mecA
of methicillin-resistant S. aureus (MRSA), one of the most pre-
valent AMR pathogens worldwide28. We optimized the spacer
sequences (Supplementary Fig. 6b–e) and the CRISPR-
Cas13a_mecA-carrying vector (pKLC-SP_mecA) construction
were carried out in the same way as above for CRISPR-
Cas13a_blaIMP-1. The packing of CRISPR-Cas13a_mecA into S.
aureus phage 80α capsid was performed in accordance with the
method established by Ubeda et al. using the S. aureus patho-
genicity island (SaPI) system29,30 (Supplementary Fig. 7). This
packing system simultaneously imparted tetracycline (Tet) resis-
tance to the resulting SA-CapsidCas13a::TetR_mecA construct,
since the SaPI carried the Tet resistance gene, which made it
possible to be tested for both bactericidal ability against MRSA
and capability of MRSA detection by targeting mecA. As expec-
ted, when the methicillin-susceptible S. aureus strain RN4220 and
MRSA USA300 or mecA knockout USA300 (USA300-ΔmecA)
were infected with SA-CapsidCas13a_mecA, the growth of only
the USA300 strain carrying mecA was significantly inhibited
(Fig. 5k, Supplementary Fig. 8), clearly demonstrating the
sequence-specific bacterial killing ability of CRISPR-Cas13a
against the Gram-positive bacteria S. aureus.
Discussion
In this study, we employed the promiscuous RNA cleavage ability
of CRISPR-Cas13a via recognition of target RNA by CRISPR-
RNA (crRNA), which resulted in host cell death, to generate a
new type of sequence-specific bacterial antimicrobials. To deliver
the CRISPR-Cas13a to target bacteria, we packaged the CRISPR-
Cas13a into carrier phage capsid using the PICI packaging system
for E. coli, and SaPI packaging system for S. aureus. Since syn-
thesized CapsidCas13a does not carry phage genome, it thus
belongs to the category of a nucleic acid drug or gene drug, not an
organism, thereby easily being put into practical use as a ther-
apeutic drug. Although there are still many questions to be
answered concerning practical application—such as host range of
the phage capsids, catalytic mode of Cas13a (refs. 14,15), the
efficiency of phage capsid packaging, and ethical issues regarding
genetic recombinants, etc.—our strategy demonstrated that the
CapsidCas13a antimicrobials are promising to be developed for at
least three application categories: (1) as promising antibacterial
therapeutic agents targeting any bacterial gene, including AMR
genes, or selectively killing targeted toxin-producing bacteria, (2)
as a simple and inexpensive bacterial gene detection system for
bacterial identification and efficient molecular epidemiological
investigations without the need for the amplification of nucleic
acids or optic devices, (3) as tools to manipulate the bacterial flora
by targeting and eliminating a specific bacterial population
without disrupting other irrelevant bacterial populations. In
conclusion, the proposed CRISPR-Cas13a-based antimicrobials
are expected to have a great impact in the field of antimicrobial
resistance for infection control, as well as bacterial flora control.
Methods
Ethics declarations. Ethics approval for the use of invertebrates was given by Jichi
Medical University ethics committee.
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Bacterial strains and culture conditions. Bacterial strains used in this study are
listed in Supplementary Table 1. Bacterial strains were grown at 37 °C in LB
medium (BD Difco). Unless otherwise indicated, proper antibiotics were added to
growth medium to the following final concentrations: 100 µg/mL for ampicillin
(Amp), 30 µg/mL for Km, 34 µg/mL for chloramphenicol (Cm), 4 µg/mL for
colistin, and 200 µg/mL for Hygro.
CRISPR-Cas13a and CRISPR-Cas9 gene targeting vectors. The CRISPR-Cas13a
expression vector (pC003), which carries LshC2c2 locus on pACYC184, was kindly
provided by Dr. Feng Zhang (Addgene plasmid # 79152; http://n2t.net/addgene:
79152; RRID: Addgene_79152)14. In order to generate an efficient vector series
carrying a CRISPR-Cas13a system targeting various genes, we conducted vector
manipulations. First, a DNA fragment of cas13a-cas1-cas2 locus was amplified
from L. shahii strain JCM16776 (ref. 14), using a primer set of LsCas13a clo-f and
LsCas13a clo-r (Supplementary Table 3), and another DNA fragment from the
pC003 vector was amplified, using primers pC003 PCR-r and pC003 PCR-f. The
two DNA fragments were then ligated with In-Fusion HD Cloning Kit (Takara Bio
Inc., Japan) to generate pKLC5, which resulted in the replacement of cas13a-cas1-
cas2 locus of pC003 with that of JCM16776. Next, the cas1-cas2 locus was removed
from the pKLC5, because Cas1/2 is not necessary for bactericidal activity of
CRISPR-Cas13a. This was achieved by performing PCR on the pKLC5 using a
primer set of Cas1 Cas2 del SacI-f and Cas1 Cas2 del SacI-r, digesting the PCR
fragment with SacI (Takara Bio Inc., Japan) and ligating again with Ligation high
ver. 2 (Toyobo Co., Ltd, Japan) to generate pKLC5 ΔCas1/2. Following this, in
order to enable the pKLC5 ΔCas1/2 to be packaged into M13 phage capsid, f1
origin together with KanR were inserted as follows: the f1 origin and the KanR
were amplified from pRC319, a gift from Timothy Lu (Addgene plasmid # 61272;
http://n2t.net/addgene: 61272; RRID: Addgene_61272)9, using a primer set of
InF13 pRC319-f and InF13 pRC319-r, and another primer set of InF13 PCR SalI-f
and InF13 PCR SmaI-r was used to amplify vector part from the pKLC5 ΔCas1/2
vector. The resulting two DNA fragments were then ligated with In-Fusion HD
Cloning Kit to generate pKLC21 that carries complete CRISPR-Cas13a system,
except for leaving the cloning site empty for insertion of any appropriate spacer.
The pKLC21 carries f1 origin of M13 phage thus is able to interact with M13 phage.
Finally, a CRISPR-Cas13a system targeting carbapenem-resistant gene blaIMP-1 was
constructed on the pKLC21 vector as follows: briefly, 33 mer oligo DNAs (28 mer
of spacer and 5 mer for inserting BsaI cut site) of blaIMP-1_104-s and blaIMP-
1_104-as, corresponding to nucleotide positions of blaIMP-1 from no. 104 to no.
132, were synthesized and annealed in annealing buffer (10 mM Tris-HCl (pH 8.0),
50 mM NaCl, and 1 mM EDTA). After that, pKLC21 was treated with restriction
enzyme BsaI-HF, gel purified and subsequently ligated with the annealed oligo
DNA using Ligation high ver. 2 to obtain pKLC21_blaIMP-1_104. Likewise, a series
of pKLC21 vectors targeting other carbapenem-resistant genes (blaNDM-1, blaKPC-2,
blaOXA-48, and blaVIM-2), colistin-resistant genes (mcr-1 and mcr-2), and mecA,
rpsE, and ermC of S. aureus were produced. The blaIMP-1-targeting pKLC21 vector
library covering the whole sequences of blaIMP-1 was also constructed in the same
manner, whereby 121 different oligo DNAs pairs covering the whole blaIMP-1 were
inserted into the BsaI site of pKLC21. The sequences of all oligo DNAs used were
listed in the Supplementary Table 3. Apart from pKLC21 vector series, S. aureus–E.
coli shuttle vector carrying CRISPR-Cas13a (pKLC3.0) was also constructed. For
the assembly of pKLC3.0, three DNA segments, KanR (aphA-3) and ori of E. coli,
cat and p15A ori of S. aureus, and cas13a were amplified from pHel3-FLAG
(ref. 31), pDB114 (kindly provided by Dr. Luciano Marraffini)10 and pKLC21,
respectively, using the following primer sets (Supplementary Table 3): InF 3.0
KanR-f and InF 3.0 KanR-r; InF 3.0 SArep_CAT-f and InF 3.0 SArep_CAT-r; and
InF 3.0 p15A ori_Cas13-f and InF 3.0 p15A ori_Cas13-r. The resulting three
fragments were ligated with In-Fusion HD Cloning Kit to generate pKLC3.0. For
the PICImid (plasmid carrying the PICI packaging system) construction, the cosN
and rppA genes (ref. 25), which are necessary for the packaging of the island
EcCICFT073, were cloned. These were amplified with a primer set of InFpi ara-
CosPPi NotI1-f and InFpi araCosPPi NotI1-r. The resulting fragment was digested
with NotI (Takara Bio Inc., Japan) and subsequently cloned into the NotI site of
pKLC21 to generate PICImid pKLC31. To construct CRISPR-Cas9 expression
vector, pYS29 vector32 was digested by PstI. The fragment containing CRISPR-
Cas9 was ligated with a PCR fragment of pKLC21 that was amplified using a
primer pair InF54 pKLC21 PCR-f and InF54 pKLC21 PCR-r to generate pKLC54.
A spacer sequence against blaIMP-1 was inserted into the BsaI site of pKLC54 vector
to obtain pKLC54_blaIMP-1_560 using Ligation high ver. 2. Oligo DNAs used for
the spacer construction are listed in Supplementary Table 3.
S. aureus–E. coli CRISPR-Cas13a_mecA shuttle vector. We constructed the
vector pKLC-SP_mecA that carries CRISPR-Cas13a_mecA sequences flanked by
two homologous recombination regions from bap (encoding biofilm associated
protein) of staphylococcal SaPIbov2 on the S. aureus–E. coli vector pIMAY. Two
PCR fragments of 5′ and 3′ regions of bap on SaPIbov2 were first amplified from S.
aureus strain RN4220-80α-ΔterS-SaPIbov2::tetM (refs. 29,33). The primers BAPup
7272-F and BAPup 8172-R were used for the PCR amplification of the 5′ region of
bap gene, while primers BAPdown 12224-F and BAPdown 13089-R were used to
amplify the 3′ region. The two fragments with 15-bp flanking sequences homo-
logous to vector ends were then sequentially integrated into a temperature-sensitive
plasmid pIMAY, using In-Fusion HD Cloning Kit generating pIMAY-bapUp/
Down. Meanwhile, we used pKLC21_mecA-5 as a template for amplification of
CRISPR-Cas13a_mecA with spacer targeting mecA and a CRISPR-Cas13a system
devoid of spacer targeting mecA (CRISPR-Cas13a_nontargeting). The PCR
amplification was carried out with primer pairs of LsC2c2 mecA5-F and LsC2c2
mecA5-R to obtain CRISPR-Cas13a_mecA, and LsC2c2 mecA5-F and LsC2c2 188-
R to obtain CRISPR-Cas13a_nontargeting (control). Finally, we individually
inserted the PCR products between the 5′ and 3′ region of bap on pIMAY-bapUp/
Down with In-Fusion HD Cloning Kit to generate pKLC-SP_mecA and pKLC-
SP_null (control).
Construction of target gene expression vectors. We constructed two plasmid
systems for expression of target genes of the CRISPR-Cas13a systems: a pSP72 aTc-
inducible vector in which the cloning site for target gene expression was under the
control of aTc; and pKLC26 that does not contain f1 origin of replication from
M13 phage. For the construction of pSP72, aTc-regulatory element was first
amplified from pC008 vector using TetReg SalI-f and TetReg BamHI-r primers,
and the amplicon was digested with restriction enzymes SalI and BamHI. After
digestion, the fragment was inserted into the SalI–BamHI site of pSP72 vector
(Promega Corporation, US) carrying pBR322 origin. The resulting plasmid was
termed as pSP72 aTc-inducible vector because the cloning site (BamHI/EcoRI) for
expression of target gene is regulated by aTc-inducible promoter.
The pC008 (pBR322 with Tet-inducible RFP) was a gift from Feng Zhang
(Addgene plasmid # 79157; http://n2t.net/addgene: 79157; RRID: Addgene_79157)14.
A subsequent set of vectors expressing target genes for CRISPR-Cas13a was produced
by cloning AMR genes (e.g., blaIMP-1, blaNDM-1, blaKPC-2, blaOXA-48, and blaVIM-2) on
the BamHI/EcoRI site of the generated plasmid. The pKLC26 was constructed by
modifying pBAD33 with deletion of f1 origin and ARA-promoter. First, pBAD33
vector was amplified with two primers, pBAD33 PCR XhoI-f and pBAD33 PCR
XhoI-r, which were designed to exclude f1 origin. After digestion with restriction
enzyme XhoI, the fragment was self-ligated with Ligation high ver. 2 to generate
pKLC23. Then, the pKLC23 vector and blaIMP-1 native promoter sequence (1,716-
1,168 bp of GenBank ID: AB733642.1 artificially synthesized by GENEWIZ) were
independently amplified with two primer sets, pKLC23 PCR InFusion-f2 and pKLC23
PCR InFusion-r2, and InFusion-f and Intl1pro InFusion-r, respectively. Combination
of the resulting two fragments with In-Fusion HD Cloning Kit finally generated
pKLC26 vector, which carries blaIMP-1 native promoter in replacement of ARA-
promoter.
To obtain pKLC26_blaIMP-1 for blaIMP-1 expression, two PCR amplifications
were carried out, generating a fragment of pKLC26 using a primer pair InF18
pKLC26-f and InF18 pKLC26-r, and a fragment of blaIMP-1 (GenBank ID: S71932)
using a primer pair InF18 IMP-1-f and InF18 IMP-1-r. The two DNA fragments
were then ligated with In-Fusion HD Cloning Kit to yield pKLC26_blaIMP-1. By
using the same method, a series of vectors for expression of the following AMR
genes were generated (Supplementary Table 2): blaNDM-1 (GenBank ID:
FN396876), blaKPC-2 (GenBank ID: AY034847), blaVIM-2 (GenBank ID: AF191564),
blaOXA-48 (GenBank ID: AY236073), mcr-1 (GenBank ID: KP347127), mcr-2
(GenBank ID: LT598652), hygroR (the sequence was subcloned from TOPO
HygroR that was a gift from Tyler Jacks, Addgene plasmid # 68445), and rfp
(encoding RFP, GenBank ID: KJ021042).
To yield pKLC26_blaIMP-1_mcr-2, two PCR amplifications were carried out,
generating a fragment of pKLC26_blaIMP-1 using a primer pair InF55 pKLC26IMP1-f
and InF55 pKLC26IMP1-r, and a fragment of pKLC26_mcr-2 using a primer pair
InF55 pKLC26mcr2-f and InF55 pKLC26mcr2-r. The two DNA fragments were then
ligated with In-Fusion HD Cloning Kit. We confirmed the expressions of cloned
genes by susceptibility test against corresponding antibiotics using the disk diffusion
test recommended by CLSI. To obtain pKLC42 for hygroR expression under the
control of RecA promoter, PCR amplifications were carried out, generating a
fragment of pKLC26_HygroR using a primer pair InF42 HygroR-f and InF42
HygroR-r. The PCR fragment and synthesized RecA promoter oligo DNA
(Supplementary Table 3) were then ligated with In-Fusion HD Cloning Kit.
Construction of the pKLC53 was carried out as follows. The RecA promoter was
amplified from the pKLC42 using a primer set of InF53 pKLC42 PCR-r and InF53
pKLC42 PCR-f, and the IMP-1 expression sequence was amplified from
pKLC26_blaIMP-1, using primers of InF53 IMP-1 PCR-f and InF53 IMP-1 PCR-r.
The two amplicons were then ligated with In-Fusion HD Cloning Kit to generate
pKLC53. To obtain pKLC56_blaIMP-1 for blaIMP-1 expression under the control of
Tet-inducible promoter, two PCR amplifications were carried out, generating a
fragment of pKLC26_blaIMP-1 using a primer pair InF56 pKLC26_IMP-1-f and InF56
pKLC26_IMP-1-r, and a fragment of pSP72 aTc-inducible vector using a primer pair
InF56 Tet-ind clo-f and InF56 Tet-ind clo-r. The two DNA fragments were then
ligated with In-Fusion HD Cloning Kit. By using the same method, aTc-inducible
RFP vector and the control vector were generated (Supplementary Table 2).
Generation of M13 phage-based EC-CapsidM13Cas13a. First, to prevent M13
phage genome from self-assembly, the f1 origin of replication of the helper phage
M13KO7 (New England Biolabs, US) was deleted. This was achieved by per-
forming PCR on M13KO7 plasmid using primer pair of M13KO7 PCR InFusion-f
and M13KO7 PCR InFusion-r, and subsequently ligating the resulting fragment
with another PCR product carrying p15A origin and Cm-resistant gene, which was
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amplified from pBAD33 using a primer pair of pBAD33 PCR InFusion-f and
pBAD33 PCR InFusion-r. The ligation was performed with In-Fusion HD Cloning
Kit and the resulting phagemid was termed pKLC25. Next, CRISPR-Cas13a-loaded
E. coli M13 phage capsid targeting blaIMP-1 (M13 phage-based EC-CapsidM13-
Cas13a_blaIMP-1) was generated as follows: pKLC25 vector was transformed into
E. coli MC1061 to synthesize helper phage (phage capsid).
The transformed bacteria were selected on Cm plates. Subsequently, the E. coli
harboring pKLC25 was transformed with pKLC21 that carries CRISPR-Cas13a and
f1 origin of M13 (i.e., pKLC21_blaIMP-1 vector), and selected on the LB agar
containing Cm and Km. The colonies grown on this double antibiotic selection
plate were picked and cultured in LB liquid medium containing Cm and Km at
37 °C. E. coli cultures at stationary phase were then centrifuged at 8000 × g for
20 min and the supernatant was passed through a 0.22 µm filter. Equal volume of
PEG buffer (5 mM Tris-HCl (pH 7.5), 10% PEG 6000, 1 M NaCl (58 g/L), and
5 mM MgSO4·7H2O (1.23 g/L)) was added to the filtrate, mixed well, and left at
4 °C for 24 h. After that, mixtures were centrifuged at 12,000 × g for 10 min at 4 °C
to pellet the M13 phage-based EC-CapsidM13Cas13a_blaIMP-1. To improve its
purity, repeated centrifugation was carried out. Eventually, SM buffer (50 mM Tris-
HCl (pH 7.5), 0.1 M NaCl, 7 mM MgSO4·7H2O, and 0.01% gelatin) was added and
the pellet was resuspended to generate a final solution of the M13 phage-based EC-
CapsidM13Cas13a_blaIMP-1. A series of M13 phage-based EC-CapsidM13Cas13a
(s) targeting the genes of blaNDM-1, blaKPC-2, blaVIM-2, blaOXA-48, mcr-1, mcr-2, and
rfp were also prepared by using the same methods.
Generation of PICI-based EC-CapsidCas13a and EC-CapsidCas9. The E. coli
JP12507 (ref. 25), derived by lysogenizing phage Φ80 into E. coli 594 strain, was
used for the generation of PICI-based EC-CapsidCas13a(s). To prevent Φ80 from
being self-packaged during generation of PICI-based EC-CapsidCas13a, the cosN
site necessary for phage DNA packaging was deleted to create JP17091. By using
JP17091 and a series of PICImid pKLC31s, PICI-based EC-CapsidCas13a(s)::KanR
targeting various genes were generated as follows. First, the pKLC31_blaIMP-1 was
transformed into JP17091, and the transformants were cultured on Km-containing
LB plates. Then, several colonies were isolated and further cultured at 37 °C with
shaking in LB liquid medium containing Km together with adding mitomycin C
for induction of prophage excision and L-arabinose for induction of rppA (for
phage DNA packaging). The L-arabinose was added to a final concentration of
0.2% that allowed it to reach its final concentration of 2 µg/mL when the bacteria
culture reached to OD600 of 0.1. The cultures were incubated overnight at 30 °C
with shaking at 80 r.p.m. After incubation, the supernatant was harvested and
passed through a 0.22 µm filter. The same amount of PEG buffer was then added
and the solution was left at 4 °C for at least 1 h after being mixed well. Then, the
solution was centrifuged at 12,000 × g for 10 min at 4 °C, resulting in precipitation
of PICI-based EC-CapsidCas13a::KanR_blaIMP-1.
To remove residual liquids, the pellet was washed several times and finally
resuspended in SM buffer for further use. A series of PICI-based EC-CapsidCas13a::
KanR(s) targeting the genes of blaNDM-1, blaKPC-2, blaVIM-2, blaOXA-48, mcr-1, mcr-2,
and rfp were also prepared by using the same methods. The PICI-based EC-
CapsidCas13a::HygroR carrying hygroR instead of kanR was generated by using
plasmid pKLC44, in which kanR was replaced by hygorR. We constructed the
pKLC44 by cutting the pKLC31 with SacI and XhoI and combining it with hygroR
amplified from pKLC26 HygroR with the primer pair of InF44 pKLC42-f and InF44
pKLC42-r, using In-Fusion HD Cloning Kit. We generated PICI-based EC-
CapsidCas9 targeting blaNDM-1 (EC-CapsidCas9_blaNDM-1), using the
JP17091 strain and plasmid pKLC27 (carrying CRISPR-Cas9_blaNDM-1, rppA and
packaging site cosN). The pKLC27 was constructed as follows. The CRISPR-
Cas9_blaNDM-1 was amplified from the pCR319 (a gift from Timothy Lu)9 using
primer a set of InF27 pRC319-f and InF27 pRC319-r, and the packaging site cosN
and rppA were amplified from pBAD18 cosN rppA using primers of InF27
araCosPPi-f and InF27 araCosPPi-r. The two amplicons were then ligated with In-
Fusion HD Cloning Kit to generate pKLC27. The vector for PICI-based EC-
CapsidCas9 targeting blaIMP-1 (EC-CapsidCas9_blaIMP-1) was generated by
replacing CRISPR-Cas13a of pKLC31 with CRISPR-Cas9 using two restriction
enzymes, SbfI and BglII.
Generation of SaPI-based SA-CapsidCas13a_mecA. The SaPI-based SA-Capsid-
Cas13a_mecA was generated basically using a SaPI packaging system11,30. First, the
S. aureus–E.coli shuttle vector pKLC-SP_mecA carrying CRISPR-Cas13a_mecA tar-
geting mecA of MRSA and the control vector pKLC-SP_null were individually
transformed into S. aureus strain RN4220-80α-ΔterS-SaPIbov2::tetM29,33 by electro-
poration, using NEPA21 electroporator (Nepa Gene Co., Ltd., Japan) with the fol-
lowing parameters: poring pulse (voltage: 1800 V, pulse length: 2.5ms, pulse interval:
50ms, number of pulse: 1, and polarity: +) and transfer pulse (voltage: 100 V, pulse
length: 99ms, pulse interval: 50ms, number of pulse: 5, and polarity: ±).
The resulting transformants were then recovered at a temperature that
permitted plasmid replication (28 °C) for 1 h and plated on tryptic soy agar
(TSA) plates supplemented with 10 µg/mL Cm. The plasmid can be integrated
into the chromosome by homologous recombination when the transformants
were incubated at 37 °C (nonpermissive temperature) in the presence of Cm. To
stimulate rolling cycle replication, single colonies (from 37 °C plate) were then
inoculated into tryptic soy broth and incubated at 28 °C without antibiotic
selection. Finally, 100 µl of the 10−5 dilution of this culture was plated on TSA
with 1 µg/mL aTc to select cells free of plasmid. Insertion of both CRISPR-
Cas13a systems was validated by PCR. Finally, resulting cells were chemically
induced by mitomycin C to generate SA-CapsidCas13a_mecA and SA-
CapsidCas13a_nontargeting (control) by using the method described
elsewhere11.
E. coli strain with chromosomally integrated genes. The generation of E. coli
strain expressing foreign gene on its own chromosome was carried out by using
ARA-inducible Red recombination system. First, we transformed E. coli strains
NEB5-alpha F′Iq (New England Biolabs, US) and MC1061 with plasmid pKD46
that carries ARA-inducible Red recombination system34. Next, the desired genes,
e.g., blaIMP-1, were knocked-in into the above strains following the methods
described by Tomoya Baba et al.35. A DNA fragment containing blaIMP-1 and Cm
resistance gene (cat) was amplified from the pKLC26_blaIMP-1 with a primer pair of
K12 genome-in pKLC26-f and K12 genome-in pKLC26 Cm-r, and the PCR pro-
duct was electroporated into the above E. coli cell using ELEPO 21 with the
following parameters: poring pulse (voltage: 2000 V, pulse length: 2.5 ms, pulse
interval: 50 ms, number of pulses: 1, and polarity: +) and transfer pulse (voltage:
150 V, pulse length: 50 ms, pulse interval: 50 ms, number of pulses: 5, and polarity:
±). After electroporation, 1 mL of SOC was added and the mixture was cultured at
37 °C for 1 h with agitation, before spreading on LB plate containing Cm and
further incubated at 37 °C until colonies were observed. The sequence of the
resulting insertion was confirmed by Sanger sequencing.
Bacterial cell growth inhibitory test on plate. The pKLC21_blaIMP-1_563 (Cas13a
and crRNA_blaIMP-1_563 expression plasmid) and the pKLC54_blaIMP-1_560 (Cas9
and crRNA_blaIMP-1_560 expression plasmid) targeting blaIMP-1 were constructed
as mentioned above. The CRISPR-Cas expression plasmid was transformed into
E. coli STBL3(pKLC45) (as a control) and STBL3(pKLC53) (blaIMP-1 expression
plasmid). Each transformant was then plated onto LB plates containing Km, and
incubated at 30 °C for 16 h. After that, colonies on the plates were collected and
serially diluted with 0.8 % NaCl, and a colony count for the number of surviving
cells was carried out.
Bacterial cell growth inhibitory test in culture medium. The pKLC21_blaIMP-1_563,
the pKLC21_blaIMP-1_RFP and the pKLC21_blaIMP-1_nontargeting were transformed
into E. coli STBL3(pKLC56) (as a control), STBL3(pKLC56_blaIMP-1) (aTc-inducible
blaIMP-1 expression plasmid), and STBL3(pKLC56_RFP) (aTc-inducible RFP expres-
sion plasmid). Each transformant was then plated onto LB plates containing Km and
Cm, and incubated at 37 °C for 16 h. The colonies on the plates were transferred to an
LB culture medium containing Km and Cm, and incubated at 37 °C for 10 h. After
confirming that the bacteria had grown well, each culture was diluted 100-fold with LB
medium, and incubated at 30 °C for 1.5 h with vigorous shaking (400 r.p.m.). Then,
1 µg/mL aTc was added to induce the expression of blaIMP-1 and rfp, and incubated at
30 °C for 1 h with vigorous shaking. After that, antibiotics (Km and Cm, and Amp)
were added into the culture, and incubated at 30 °C for 23 h with vigorous shaking.
OD650 of each well was monitored every hour.
Cell viability test after introducing CRISPR-Cas13a. The pKLC21_blaIMP-1_563
was transformed into E. coli STBL3(pKLC56_blaIMP-1) and the bacteria was plated
onto LB plates containing Km and Cm, and incubated at 37 °C for 16 h. The
colonies on the plates were transferred to an LB culture medium containing Km
and Cm, and incubated at 37 °C for 10 h. The bacterial culture was diluted 100-fold
with LB medium, then 1 µg/mL of aTc and the antibiotics Km and Cm were added,
followed by incubation at 30 °C for 8 h. The bacteria culture was vigorously shaken
for 10 s every 1 h just prior to measuring OD. The bacteria were collected at the
time point of 0 h, 1 h, 2 h, 4 h, and 8 h after the treatment, and serially diluted with
0.8% NaCl. Diluted bacteria were spotted on the LB plate without antibiotics and
the number of surviving cells were counted.
Sequence-specific bacterial killing by EC-CapsidCas13a. The logarithmic phase
cultures of three E. coli strains with overexpression of blaIMP-1, mcr-2 in plasmid
and carrying control plasmid, NEB5-alpha F′Iq (pKLC26_blaIMP-1), and NEB5-
alpha F′Iq (pKLC26_mcr-2) and NEB5-alpha F′Iq (pKLC26), in LB liquid medium
were adjusted to an OD600 of 0.1, and diluted ten times with fresh LB medium. We
transferred 300 μl of each dilution into one tube, mixed well, then divided them
into four tubes up to 100 μl for each tube. Three tubes were treated with M13-based
EC-CapsidCas13a_blaIMP-1, EC-CapsidCas13a_mcr-2, and EC-CapsidCas13a_
nontargeting (control), respectively, while the fourth tube was regarded as non-
treated control. EC-CapsidCa13a treatments were carried out by individually
adding MOI 100 of the above three CapsidCas13a(s) to their corresponding tubes,
mixing well, then culturing at 37 °C with gentle shaking for 6 h. After incubation,
serial dilutions were made with 0.8% NaCl and a colony count for the number of
survived cells was carried out. The number of colonies that formed on the agar
plates containing Amp, colistin, and drug free, respectively, were counted, and cell
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16731-6 ARTICLE
NATURE COMMUNICATIONS | (2020)11:2934 | https://doi.org/10.1038/s41467-020-16731-6 | www.nature.com/naturecommunications 9
ratios were calculated. The sequence-specific killing activity of SA-CapsidCas13a_
mecA was determined by using Tet agar plate, since SA-CapsidCas13a(s) generated
were carrying Tet resistance determinant delivered from SaPIbov2 during the
packaging processes.
Measurement of phage titers. The M13 phage/PICI-based EC-CapsidCas13a(s)
were serially diluted with SM buffer ranging from 10−4 to 10−7. In the mean-
time, overnight culture of E. coli strain NEB5-alpha F′Iq or MC1061 diluted
1:100 with LB broth was incubated with agitation at 37 °C until an OD600 of ~0.1
was obtained. Then, 10 µl of each dilution of M13 phage/PICI-based EC-Cap-
sidCas13a(s) was added to 100 µl of bacterial suspension and the mixture was
incubated at 37 °C for 30 min. Subsequently, all of the culture solution was
plated on LB plates containing Cm or Km, and the plates were incubated
overnight at 37 °C. The colonies grown on the Km plate but not on the Cm were
counted to calculate the TFU/mL.
Detection of bacterial genes with CapsidCas13a(s). The E. coli strains to be
determined were grown to an OD600 of ~0.5. Then, 100 µl of the culture were
mixed with 3 mL molten soft agar (LB solution with 0.5% agarose) prewarmed at
50 °C and poured onto an LB plate containing Km or Hygro. The plates were
solidified at room temperature. Meanwhile, M13 phage/PICI-based EC-
CapsidCas13a with known titers was adjusted to 105 TFU/mL and its tenfold
serial dilutions were prepared. Finally, 2 µL of each dilution of the M13 phage/
PICI-based EC-CapsidCas13a were spotted onto the solidified soft agar and the
plates were incubated at 37 °C. The result was interpreted as positive if bacter-
icidal plaque formed on the plate.
pKLC21_blaIMP-1 library sequencing. The pKLC21_blaIMP-1 (CRISPR-Cas13a_-
blaIMP-1 expression plasmid) library targeting the whole region of blaIMP-1 was
constructed as aforementioned. Equal amounts of each of the 121 pKLC21_blaIMP-1
carrying spacers against different position of blaIMP-1 and pKLC21_nontargeting (as
a control) were mixed and transformed into E. coliMC1061(pKLC26) and MC1061
(pKLC26_blaIMP-1). Each transformant was then plated onto 20 LB plates con-
taining Cm and Km, and incubated at 37 °C for 16 h. Next, >10,000 colonies for
each transformant were harvested by using LB medium, and plasmids were
extracted using QIAGEN Plasmid Midi Kit (QIAGEN). Pair-end sequencing
libraries were constructed from the plasmids using Nextera XT Library Prep Kit
(Illumina). Sequencing was performed using Illumina MiSeq platform (2 × 301 bp)
with MiSeq reagent kit version 3 (Illumina).
G. mellonella survival assay. The M-sized G. mellonella larvae purchased from
Ikiesa factory (Osaka, Japan) were used for the survival assay to assess the effect
of PICI-based EC-CapsidCas13a on treatment of E. coli infections. Upon receipt,
the larvae were acclimated to the laboratory environment by leaving them in a
dark room for 24 h before starting the assay. Larvae with weak movement, dark
color, unusual shape, and sizes that differed distinctly from other larvae were
excluded from the experiment. A Hamilton syringe (701LT, Hamilton) and a KF
731 needle (Hamilton) were used in this experiment. First, overnight culture of
carbapenem-resistant E. coli R10-61 carrying the carbapenem resistance gene
blaIMP-1 was diluted at 1:1000 with fresh LB medium and further incubated at
37 °C with agitation to reach an OD600 of ~0.5. The bacteria were then washed
twice with PBS and adjusted to a density of ~1 × 107 CFU/mL in PBS. Thirty
cream-colored larvae for each group were selected and 5 µl of bacterial sus-
pension was directly injected into the left proleg. One hour later, 5 µl of PBS
containing MOI 100 of PICI-based EC-CapsidCas13a_blaIMP-1, EC-CapsidCa-
s13a_nontargeting, or PBS only, were injected into the same site where bacteria
solution had been injected. The larvae were transferred to a 37 °C incubator, and
the survival was monitored for up to 3 days. Larvae that did not respond to
stimulation with needles or whose bodies deformed were counted as dead.
Kaplan–Meier survival curves were then generated from data of three inde-
pendent experiments and analyzed with log-rank test using software EZR (http://
www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmedEN.html).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this Article.
Data availability
The data that support the findings in this study are available upon reasonable request
from the corresponding author. Data supporting the findings of this study are available
within the Article and Supplementary Information. Bacteria list, plasmid list, primer list,
and the screening results are available in the Supplementary Tables. Figures 1c, e, f, 3 and
4, and Supplementary Figs. 1, 2, 6a, e are provided as a Source Data file.
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